Neuromodulator and injectable advertising: what med spas can say about prescription treatments

Wrinkle-relaxing injections are prescription drugs. For a med spa, dermatology office or plastic surgery practice, that makes a neuromodulator special or a social post about “units” different from an ad for a facial or a peel: there is an FDA-approved label behind the product, with approved uses, risk information and in some cases a boxed warning, and there are FDA rules on how the drug itself is advertised. The question for a clinic is which of those rules bind it directly and which ones are still the right yardstick.

This guide covers that question for neuromodulator and other prescription injectable ads: who FDA’s drug ad rules bind, how to present benefits and risks, what to do about brand names and price specials, and how injector and influencer posts fit under the FTC endorsement guides. We do not name any drug or brand. Our guide to advertising a prescription treatment covers the FDA and FTC split, off-label use and compounded drugs in general; this guide applies it to injectables. For ad platform rules, see Google Ads for med spas. For lip, cheek and wrinkle fillers, see our guide to dermal filler advertising rules. For thread lifts and how thread clearances limit lift claims, see our guide to thread lift advertising rules. For underarm sweating injections and the other hyperhidrosis treatments, see our guide to hyperhidrosis treatment marketing.

The short version

• FDA’s drug ad rule binds the manufacturer, packer or distributor. 21 USC 352(n) applies to advertisements “issued or caused to be issued by the manufacturer, packer, or distributor”. A clinic’s own ads are governed mainly by the FTC Act (15 USC 52, 55). If a maker or distributor pays for, supplies or approves your ad, ask counsel whether it is theirs too.
• Fair balance is still the right yardstick. FDA’s rule treats a drug ad as misleading when benefits get more scope, depth or detail than the risk information (21 CFR 202.1(e)(5)(ii)). The FTC Act reaches ads that fail to reveal material facts, including consequences of use (15 USC 55(a)(1)).
• Check the label for a boxed warning. FDA uses a boxed warning for serious warnings, particularly those that may lead to death or serious injury (21 CFR 201.57(c)(1)), and its rule does not allow manufacturer reminder ads, other than those solely conveying price, for a drug whose labeling has one (21 CFR 202.1(e)(2)(i)). Read the label of the product you use before you write the ad.
• Stay inside the approved uses. A manufacturer’s ad may not suggest a drug is useful in a broader range of conditions or patients than the labeling permits (21 CFR 202.1(e)(6)(i)). Off-label treatment may be a medical decision; advertising it is a different question.
• Free treatment for posts is a material connection. Free or discounted products given to an endorser count, whether or not a post is required in return, and must be disclosed clearly and conspicuously (16 CFR 255.5(a)).

Who FDA’s drug ad rules bind

21 USC 352(n) treats a prescription drug as misbranded unless the manufacturer, packer or distributor includes, in all advertisements and other descriptive printed matter it issues or causes to be issued for that drug, a true statement of the established name, the quantitative formula and a brief summary of side effects, contraindications and effectiveness as FDA’s regulations require. 21 CFR 202.1 fills in those duties: what counts as an advertisement (202.1(l)(1)), what a brief summary must contain, and when an ad is false, lacking in fair balance or otherwise misleading (202.1(e)(5), (6)).

A clinic is not usually the manufacturer, packer or distributor of the injectables it uses, so its own ads fall mainly under the FTC Act: 15 USC 52(a) bars false advertisements likely to induce the purchase of drugs or services, and 15 USC 55(a)(1) defines a false advertisement as one misleading in a material respect, including by failing to reveal facts material to the representations made or to the consequences of using the product as advertised. Our guide to advertising a prescription treatment covers that split and the FTC and FDA working arrangement in more detail.

Two cautions follow. First, the line between a clinic’s ad and a maker’s ad is not always clear when the maker or a distributor supplies the creative, funds the placement or runs a loyalty or rebate program the ad promotes. We did not read any co-op program terms; ask counsel before you run maker-supplied material. Second, even where 202.1 does not bind you, it describes what FDA considers misleading about prescription drug ads, and the FTC Act’s material-facts standard points the same way.

Presenting benefits and risks

FDA’s rule says an ad does not present a true statement of side effects, contraindications and effectiveness if it is false or misleading on those points, or if it “fails to present a fair balance between information relating to side effects and contraindications and information relating to effectiveness of the drug” because effectiveness gets more scope, depth or detail than the risk information (21 CFR 202.1(e)(5)(i), (ii)). For a clinic page, the practical translation is:

• If the page describes what the treatment does, it also says what can go wrong, in the same place and at a similar level of detail, taken from the product’s labeling, not from memory or a competitor’s site.
• Results and duration claims (“lasts six months”, “no downtime”, “no side effects”) need support. The FTC Health Products Compliance Guidance says health benefit claims need competent and reliable scientific evidence, and that advertising making an express or implied safety representation should include information about any significant safety risks.
• Link to the full prescribing information or the patient information for the product you use, and say that a licensed clinician decides whether the treatment is appropriate at a consultation.
• If the labeling carries a boxed warning, do not leave its subject out of any page that promotes the treatment. FDA describes boxed warnings as reserved for certain contraindications or serious warnings, particularly those that may lead to death or serious injury (21 CFR 201.57(c)(1)).

FDA’s rule also lists, among the ways an ad can be misleading, a representation or suggestion not approved or permitted in the labeling that a drug is better, more effective, or useful in a broader range of conditions or patients (21 CFR 202.1(e)(6)(i)). For injectables, that covers ads for areas of the face or body, or for conditions, that the product is not approved for. A clinician may decide to treat off-label; that does not make it safe to advertise the off-label use as if it were approved.

Brand names, units and price specials

Promotions are where injectable ads get specific: a brand name, a price per unit, a “first-time” offer, a holiday event or a membership. Points to check:

• Use the name of the product you actually inject. If an ad names a brand and the patient receives a different product, the ad misrepresents the service (15 USC 52, 55).
• Unit prices. A low per-unit price is only meaningful if the ad says how many units a typical treatment area takes at your clinic, or that the number is set at consultation. Our guide to advertising cash prices covers “starting at” and package wording.
• Was/now and event pricing. A former price must be real; see our guide to was/now sale price claims.
• Gift cards and group events. See our guide to med spa gift card and promotion rules. A prescription treatment still needs an individual clinical decision; promotions should not imply that a purchase guarantees treatment.
• Paid search. Prescription drug names are restricted terms in Google Ads; our Google Ads for med spas guide covers what that means for keywords, ad text and landing pages.

Injector posts, model calls and influencers

Injectable content on social media takes several forms: injector accounts, patient videos, “model calls” offering free or discounted treatment, and creator partnerships. The FTC endorsement guides apply to all of them.

Under 16 CFR 255.5(a), when a connection between the endorser and the seller might materially affect the weight or credibility of the endorsement, and the audience would not expect it, the connection must be disclosed clearly and conspicuously. Material connections include a business, family or personal relationship and “the provision of free or discounted products … to an endorser, regardless of whether the advertiser requires an endorsement in return.” A model who received free treatment and posts about it, an employee posting from a personal account, and a creator paid in services all have material connections to disclose.

Under 16 CFR 255.2(a), consumer endorsements about a product’s performance are read as claims that the product works for the purpose shown, so the clinic needs the same evidence it would need to make the claim itself. Under 255.2(b), a result on a key attribute is read as typical unless the ad clearly discloses what patients generally achieve. Before-and-after posts are endorsements in this sense; see our guide to testimonials and before-and-after photos for consent and HIPAA, and healthcare influencer marketing for creator contracts.

Who injects, and how to describe them

Rules on who may inject prescription neuromodulators and fillers, under what supervision, and who must examine the patient first, are set by each state’s medical, nursing and pharmacy boards, and we did not read them for this guide. Whatever your state allows, describe each injector’s license and role accurately. “Master injector”, “expert” and “certified” are factual claims under 15 USC 52 when they are used to sell a service; use them only if you can say what they mean and who granted them.

An illustration

This is a made-up example, not a client. A med spa runs a social ad for “$9 units, this weekend only, results that last, zero downtime”, naming a brand, with a reel from a creator who was treated free. The landing page lists treatment areas including one not in the product’s approved uses and has no risk information.

The fix: the ad names the product the clinic actually uses and states that the number of units is set at consultation. “This weekend only” stays because it is true; any “regular price” is removed unless the clinic has charged it. “Zero downtime” and “results that last” come out; the page instead gives the duration range and the side effects from the product’s labeling, at the same depth as the benefits, with a link to the prescribing information and any boxed warning subject named. The off-label area comes off the ad and the page. The creator’s reel adds a clear “I received this treatment free from the clinic” in the video and caption (16 CFR 255.5).

Checklist

• Ads name only the product you use, and any maker-supplied material has been reviewed by counsel (21 USC 352(n)).
• Benefits and risks presented with similar scope and depth, from the product’s labeling (21 CFR 202.1(e)(5)(ii); 15 USC 55(a)(1)).
• The product’s label checked for a boxed warning, and its subject addressed on promotional pages (21 CFR 201.57(c)(1)).
• No approved-use claims beyond the labeling (21 CFR 202.1(e)(6)(i)).
• Duration, downtime and safety claims backed by evidence (FTC Health Products Compliance Guidance).
• Unit prices explained; former prices real; promotions do not promise treatment.
• Free or discounted treatment for models, staff and creators disclosed in each post (16 CFR 255.5).
• Before-and-after posts consented and typical, or typical results disclosed (16 CFR 255.2).
• Injector titles and credentials accurate and checked against your state’s rules.

How we help

We build treatment pages, promotion landing pages and social content for med spas and aesthetic practices with drug, risk, price and endorsement claims checked against the sources above: website design, healthcare SEO and lead generation. We do not give legal opinions on FDA status, state scope of practice or manufacturer programs, and we are not a law firm. Related guides: med spa marketing ideas and med spa website design.

Sources

• 21 USC 352: Misbranded drugs and devices
• 15 USC 52: Dissemination of false advertisements
• 15 USC 55: Additional definitions
• 21 CFR 202.1: Prescription-drug advertisements
• 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products
• 16 CFR 255: Guides concerning use of endorsements and testimonials in advertising
• FTC: Health Products Compliance Guidance (December 2022)

More in Cash-pay, aesthetic and wellness care